Product details
Epitalon (also written Epithalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology as a synthetic analog of a tetrapeptide fraction isolated from bovine pineal gland (Epithalamin). The molecule has been studied since the 1980s for effects on telomerase activity, telomere length maintenance, circadian-rhythm regulation through pineal-melatonin signaling, and broader longevity readouts, making it the canonical Khavinson-class short-peptide bioregulator and the most clinically studied member of the family.
Peptuno supplies Epitalon acetate as a lyophilized powder at ≥99.0% HPLC purity. The four-residue sequence is straightforward in SPPS and the analytical packet covers peak-integration HPLC plus mass spec, sequence verification is rarely the critical test for a tetrapeptide. Standard 10 mg and 50 mg fill sizes cover both research aliquot scales and extended-research workflows. Epitalon's broad use in cyclic dosing protocols means buyers typically purchase larger fills than for most short peptides; the 50 mg vial is the more common size for sustained-research contexts.
Regulatory note: Peptuno supplies Epitalon strictly for Research Use Only; buyers are responsible for verifying ingredient eligibility in their destination market.
FAQ
- What's the relationship between Epitalon and Khavinson bioregulators more broadly?
- Epitalon is the most-studied member of the Khavinson-class short-peptide bioregulators, a research lineage developed at the St. Petersburg Institute of Bioregulation and Gerontology that includes Cortagen (AEDP), Bronchogen (AEDL), Pinealon (EDR), Vesugen (KED), and several others. The shared design pattern is short (typically 3-4 amino acids) sequences derived from tissue-specific peptide fractions isolated from animal tissues, hypothesized to act as endogenous bioregulators of cell-cycle and gene-expression programs in their respective target tissues. Epitalon is the prototype and the most rigorously studied; the others have varying levels of supporting evidence.
- Why is Epitalon under FDA PCAC review and what's the proposed indication?
- Epitalon's most consistently reported clinical effect across the Russian research literature is melatonin-pathway modulation and improvement of sleep architecture in older subjects. US regulatory frameworks for the molecule are still developing; Peptuno supplies Epitalon strictly for Research Use Only and does not opine on the destination market's specific compounding eligibility — that is the buyer's responsibility.
Certificate of Analysis (COA)
The per-lot COA for this product will appear here.